Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05805605
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:38.501997+00:00
Published At
2025-07-01T00:00:00+00:00
Record Updated At
2025-07-01
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Biphenotypic Acute Leukemia", "Undifferentiated Leukemia", "Prolymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Plasma Cell Leukemia", "Myelodysplastic Syndromes", "Leukemia, Myeloid", "Myelodysplastic Syndrome With Excess Blasts-1", "Burkitt Lymphoma", "Relapsed T-Cell Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma", "Follicular Lymphoma", "Myeloproliferative Neoplasm", "Myelofibrosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-07-01"
protocolSection.identificationModule.nctId
"NCT05805605"
protocolSection.identificationModule.officialTitle
"Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Biphenotypic Acute Leukemia (protocolSection.conditionsModule.conditions)
  • Undifferentiated Leukemia (protocolSection.conditionsModule.conditions)
  • Prolymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Plasma Cell Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Leukemia, Myeloid (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome With Excess Blasts-1 (protocolSection.conditionsModule.conditions)
  • Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Relapsed T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Relapsed Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Myelofibrosis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.